

27 July 2018

THIS DOCUMENT HAS NOT BEEN PRODUCED BY KBC SECURITIES USA, INC.


## QUEST FOR GROWTH

### 1H18 results, NAV at €8.69 p.s.

EQUITY INVESTMENT INSTRUMENTS  
BELGIUM

CURRENT PRICE €7.46  
TARGET PRICE €7.60

**HOLD**  
RATING UNCHANGED



Source: Thomson Reuters Datastream

Bloomberg	QFG BB
Reuters	QUFG.BR
<a href="http://www.questforgrowth.com">www.questforgrowth.com</a>	
Market Cap	€86.0m
Shares outst.	11.5m
Volume (daily)	€101,104
Free float	72.9%

Next corporate event

Results 3Q18: 25 October 2018

(€m)	2014	2015	2016
Net result	8.7	37.9	
Adj. net result	8.7	37.9	
Basic EPS (€)	0.76	3.29	
ROE	7.9%	34.5%	
Adj. eq. value	10.28	10.81	
Premium/disc.	26.0%	-5.5%	
DPS (€)	0.72	3.72	0.00
Dividend yield	9.5%	32.6%	

**Cédric Duinslaeger**

+32 2 429 00 55

[cedric.duinslaeger@kbcsecurities.be](mailto:cedric.duinslaeger@kbcsecurities.be)

Quest reported a slight loss of €0.56m (€0.04 p.s.) over 1H18 vs a €22m profit in 1H17. This results in an overall return of 2% (including dividend paid of €1.54 p.s.). NAV stood at €8.69 p.s. (14% discount) vs €10.71 p.s. at YE17 (18% discount).

#### Listed portfolio

Quest saw a changeable market environment with the STOXX Europe 600 Net Return Index being down 0.3% since YE17. The STOXX Europe Small 200 Net Return Index saw a rise 1.5%

Apart from the highly adverse contribution of Avantium we see a slightly positive performance of the listed portfolio with EVS (-31%) being the worst performer and Aures (+38%), Pharmagest (+35%) and Tomra (+32%) being the positive outliers. Quest sold stakes in Axway, Gerresheimer, Avantium and Bertrandt, while purchasing stakes in Akka Technologies.

#### Unlisted portfolio

Mapper's valuation was reduced to zero, loans were extended to Sequana Medical and FRX Polymers.

#### VC investments

Capricorn Cleantech's valuation has decreased (mainly due to Avantium), while we see positive developments in the Health-Tech Fund. LSP IV's valuation increased due to Argenx positive share price performance. All together we see a slight negative result in the VC part of the portfolio.

#### Our view:

Quest sees encouraging prospect for the economy's development over the short term. Overall we see performance in line with the markets.

We estimate NAV at €8.9 p.s., representing a 16% discount. No changes in our investment case.